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Intrauterine Transfusions Affect Fetal T-Cell Immunity
By Henk E. Vietor, Gail E. Hawes, Claudia van den Oever, Els van Beelen, Humphrey H.H. Kanhai, Anneke Brand,
and Peter J. Van den Elsen
Intrauterine transfusion (IUT) therapy is the treatment of 
choice in severe hemolytic disease of the fetus. This treat­
ment automatically implies the introduction of alloantigens 
in the fetal circulation, which might potentially influence the 
unprimed fetal immune system. The present study provides 
evidence that the fetal immune system is indeed prone to 
modulations of the T-cell receptor BV (TCRBV) repertoire as 
a result of IUT treatment. Most notably, IUT therapy affects 
the composition of the CD4+ repertoire, whereas this effect 
may be obscured in the CD8* subset. The CD8+ subset was 
found to be influenced by alterations of the TCRBV reper­
toire both in IUT patients and controls, suggesting that mod­
ulations in this subset could be the result of developmental 
influences. A more detailed analysis on the composition of 
the individual TCRBV families was performed by evaluating 
the distribution of the complementarity determining region
3 (CDR3) size lengths of [32P]-radiolabeled TCRBV tran­
scripts. Using this technique, referred to as spectratyping, 
only marginal changes were observed in the CD4+ and CD8+ 
subset during the course of treatment and gestational devel­
opment of both lUT-treated patients and controls. Therefore, 
the alterations in the overall TCRBV repertoire were of a 
quantitative rather than a qualitative nature. To evaluate 
whether the observed alterations in TCRBV usage-frequen- 
cies were a reflection of an allo-reactive response, a primed 
lymphocyte test (PLT) was performed in 3 lUT-treated pa­
tients. We observed that IUT, performed as early as 23 weeks 
of gestation, may induce the establishment of memory T 
cells against the IUT donor. However, there was no associa­
tion between the observed changes in TCRBV repertoire and 
the magnitude of the secondary allo-reactive response.
© 1997 by The American Society of Hematology.
DESPITE THE USE of Rhesus(D) immunoprophylaxis or deletion of allo-reactive T cells.* It has been suggestedand matching for this antigen in blood transfusion ther­
apy, approximately 1% of the Rhesus(D)-negative fertile 
women develop antibodies to erythrocyte antigens.1 Preg­
nancies complicated by severe hemolytic disease can be suc­
cessfully treated with IUT therapy. From a technical point 
of view, IUT has become an established procedure, resulting 
in a survival of approximately 90% of affected fetuses.2,3
Under physiological circumstances, the development of 
the fetal immune system occurs in an almost sterile and allo- 
antigen-free environment. Throughout gestation, the fetus is 
mainly confronted with both self and also selected maternal 
antigens. Therefore, it would not be unreasonable to assume 
that the introduction of allo-antigens into the fetal circulation 
by intrauterine transfusion (IUT) might have an impact on 
the fetal immune system. However, the immunologic conse­
quences of IUT treatment have, until now, not been investi­
gated in great detail.
Blood transfusions are known to have potent immunomod­
ulatory properties. For instance, administration of an HLA- 
(B),DR-matched blood transfusion before transplantation 
can result in an increased allograft survival.4"' This toleration 
effect might be the result of induction of anergy, suppression,
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that these transfusions result in cytotoxic T-lymphocyte non­
responsiveness to donor antigens1 and can result in the ab­
sence of several T-cell receptor BV (TCRBV) families. 
Because tolerance is easier to induce in neonates than in
10
adults, 11.12 the effect of allogeneic blood transfusion might
be even more pronounced in the fetus.
IUT treatment offers a unique model to simultaneously 
investigate the effect o f blood transfusion on the fetal im­
mune repertoire and the allogeneic response of an unprimed 
immune system in vivo. Direct access to the umbilical cord 
under ultrasound guidance has made it possible to obtain 
peripheral blood of the fetus at different time points in gesta­
tion.2’3
To evaluate semiquantitative influences of IUT therapy on 
the fetal CD4+ and CD8+ TCRBV repertoire, the polymerase 
chain reaction (PCR) technique with 25 TCRBV family- 
specific oligonucleotide primers was used to determine the 
TCRBV gene element usage both before and after IUT treat­
ment in 5 fetuses. Changes in the distribution of complemen­
tary determining region 3 (CDR3) length of the TCRs during 
the course of therapy were analyzed using spectratyping.11 
The results were compared with 5 patients who underwent 
fetal blood sampling (FBS) but did not receive IUT therapy. 
In 3 IUT-treated patients, the magnitude of the alloresponse 
against several IUT donors was determined by a primed 
lymphocyte test (PLT) in cord blood (CB), obtained ;
MATERIALS AND METHODS
IUT Patients
The use o f patient material (IUT-treated patients and controls) for 
research purposes was approved by the Commission of Medical 
Ethics of the University Hospital Leiden (protocol P244/94).
Patient and transfusion characteristics are shown in Table 1. Four 
fetuses (patients no. 1 through 4) received IUT therapy with unre­
lated donor erythrocytes for treatment o f severe hemolytic disease 
caused by Rhesus(D) antibodies. The other fetus (patient no. 5) 
received maternal platelets for management of fetal allo-immune 
thrombocytopenia, which was induced by maternal antibodies di­
rected against a paternal private antigen. The mother of this fetus
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Table 1. Patient Characteristics and Correlation Coefficient Values of the Overall Changes in the TCRBV Repertoire of Fetuses Undergoing
Diagnostic FBS or IUT
Patient No. Diagnosis No. of lUTs First FBS* Second Analysis* Birth* R2 CD4 RJ CD8
IUT patients
1. Hemolytic disease 5 21 33 (IUT5) 34 .141 .655
2. Hemolytic disease 4 21 32 (IUT4) 34 .348 .769
3. Hemolytic dlseae 2 31 37 birth 37 .851 .539
4. Hemolytic disease 2 32 39 birth 39 .193 .169
5. Allo-immune thrombocytopenia 2 28 34 (IUT3) 34 .522 .903
FBS patients
6. Growth retardation — 30 40 40 .940 .468
7. Congenital heart disease — 22 39t 38 .965 .522
8. Growth retardation — 31 3 8 i$ 35 .871 .779
9. Dandy Walker — 34 37 37 .867 .901
10. XO mosaic — 20 40 40 .851 .742
* Given in weeks of gestation.
t  Peripheral blood was obtained 1 week after birth for analysis of the TCRBV repertoire.
*  Peripheral blood was obtained 3 weeks after birth for analysis of the TCRBV repertoire.
received a high dose of intravenous gamma globulin (1 g/kg/wk) 
for 9 weeks (from 26 to 34 weeks o f gestation). Before the initiation 
of the IUT procedure, the mothers o f  IUT patients received premedi­
cation, consisting of 75 mg pethidine, 25 mg phenergan, and 50 
mg indomethacin, administered 30 minutes before the procedure. 
Pancuronium (dose depended on gestational age) was administered 
to the fetus to reduce fetal movement. This study included one pair 
of dizygotic twins, which were HLA nonidentical and of different 
gender (patients no. 1 and 2). Identification of the two fetuses before 
FBS and IUT was predicted by ultrasound.
Controls
Fetal blood was obtained from 5 fetuses of other patients (patients 
no. 6 through 10) for prenatal diagnosis (Table 1). In 2 patients, 
FBS was performed to determine the possible cause of growth retar­
dation in utero (patients no. 6 and 8). Patient no. 6 was born at 40 
weeks and had a weight o f 2,675 g. This neonate left the hospital 
in good health shortly after birth. The other infant (patient no. 8) 
was born at 35 weeks of gestation, had a weight of 890 g, and 
showed signs of dysmaturity. This child left the hospital in good 
condition 12 weeks after delivery. Patient no. 10 underwent an FBS 
procedure to confirm an XO mosaicism that was observed after 
amniocentesis. However, this diagnosis could not be confirmed in 
fetal blood, in cord blood at delivery, or in placental tissue. This 
infant left the hospital in good condition directly after birth. Ultra­
sound imaging showed multiple congenital heart defects in patient 
no. 7 and corrective heart surgery was successfully performed 3 
weeks after birth. Patients no. 7 and 8 received two blood transfu­
sions after birth for correction o f  anemia induced by laboratory 
testing. Patient no. 9 had a Dandy Walker malformation and died 
shortly after birth due to severe neurological impairment. FBS in 
control patients failed to show chromosomal aberrations or any other 
abnormalities that could explain the respective medical conditions. 
The FBS procedure in the control patients was performed without 
administration o f premedication to the mothers. Furthermore, these 
fetuses did not receive medication to prevent fetal movement.
lected in citrate-phosphate-dextrose solution. Erythrocytes were fil­
tered after buffycoat removal and contained less than 2 x  10ft 
leukocytes per unit. The hematocrit was adjusted to approximately
0.85 L/L by using 0.9% saline. Donor blood was irradiated with 25 
Gy and administered within 3 hours after preparation.
Intrauterine platelet transfusions. Maternal platelets were col­
lected using a cell separator (COBE, Lakewood, CA). After centrifu­
gation, maternal plasma was removed and platelets (containing an 
average of 50 X 106 leukocytes) were resuspended in 50-mL citrate- 
phosphate-dextrose plasma from a male, blood group AB donor. 
Maternal platelets were irradiated with 25 Gy and administered 
within 2 hours after preparation,
Collection o f  the Samples
Fetal blood was obtained by FBS in IUT patients before the onset 
of the transfusion. Immediately after birth, umbilical cord blood was 
collected before the delivery of the placenta. If this was not possible 
(patients no. 7 and 8), then peripheral blood was obtained after birth 
by venapuncture. All samples were collected in heparinized tubes, 
and 1 mL was used for TCRBV analysis. Mononuclear cells were 
isolated by Ficoll-Hypaque density gradient sedimentution within 12 
hours after collection. The cells were then frozen in liquid nitrogen 
and stored at -170°C  before fluorescence-activated cell sorting 
(FACS).
After thawing, mononuclear cells were washed twice with Hanks’ 
balanced salt solution (GIBCO, Paisley, UK) and subsequently 
stained with fluorescein isothioeyanate-eonjugated and-CD4 and 
phycoerythrin-conjugated anti-CD8 (Becton Dickinson, San Jose, 
CA) monoclonal antibody for 30 minutes at 4°C. Cells were washed 
twice in Hanks’ medium and resuspended in 50% RPMI 1640/50% 
fetal calf serum. CD4* and CD8* cells were separated using FACS 
(Becton Dickinson, Mountain View, CA) and collected in 50% 
RPMM640/50% fetal calf serum. Cells were then washed twice in 
phosphate-buffered saline at 4°C.
Preparation of IUT
Intrauterine reel blood cell (RBC) transfusions. The 1 UTs were 
prepared from fresh (< 2 4  hours) donor erythrocytes and were com­
patible with maternal erythrocyte antibodies. Donor blood was col-
RNA Isolation, t'DNA S
i
Analysis o f the TCRBV was performed using a semiquantitative 
PCR as described previously.1'1'1* RNA was isolated from the sorted
cells using the RNA/.ol method (Cinna/Biotecx Laboratories, Inc,
2494 VIËTOR ET AL
Houston, TX), dissolved in 25 /j,L o f distilled water, and stored at 
-80°C . Five micrograins of RNA was reversed-transcribed into first- 
strand cDNA using the Riboclone cDNA synthesis system (Promega, 
Madison, WI). This cDNA was first quantified with control primers 
and diluted with distilled H20  to an amount in which I f/L per 
reaction resulted in PCR products in log phase for each primer used. 
The TCRBV repertoire was analyzed using 25 TCRBV-specific 
primers identifying 24 different TCRBV families. For each PCR, 1 
/iL of cDNA was used and added to a mixture of 20 pmol of 3' 
antisense TCRBC primer, 0.5 mmol/L o f each dNTP, 10 mmoI/L 
Tris HC1 (pH 8.4), 50 mmol/L KCI, 4 mmol/L MgCl2, 0.06 
mg/mL bovine serum albumin, and 2.5 U AmpliTaq DNA polymer­
ase (Perkin/Elmer, Roche Molecular Systems, Inc, Branching;, NJ) 
and 20 pmol of each TCRBV-specific 5' sense primer in total volume 
of 100 ¡jL. Twenty-live to 35 PCR cycles were performed in a 
Thermocycler 60 (Biomed Instruments, Fullerton, CA), depending 
on the amount o f  cDNA. The PCR cycles consisted o f a 95°C dena- 
turation, a 55°C primer annealing, and a 72°C. extension step for 1 
minute each. A 5' sense primer specific for the constant region o f  
the TCR was used as an internal control. As a negative control, a 
PCR without template was performed to exclude contamination. Five 
microliters o f  the PCR-amplified products was size fractionated on 
a 1% agarose gel and subsequently transferred to a nylon filter 
(Hybond N + ;  Amersham International pic, Little Chaifont, Bucking­
hamshire, UK) for Southern analysis. The TCR/? chain-specific se­
quences were detected by hybridization with a [uP]-radiolabeled 
TCRBC-specific probe. The amount o f each individual TCRBV PCR 
product was determined using either autoradiography on Kodak 
XAR films (Eastman Kodak, Rochester, NY) and laser densitometry 
(LKB 2220-020, Ultrascan XL; Pharmacia LUB Biotechnology, 
Uppsala, Sweden) or phosphor-imaging (Phosphorlmager 445SI; 
Molecular Dynamics, Sunnyvale, CA). All PCR amplifications were 
performed in duplicate with correlation coefficients (R2) of > .9 5  
between the two analyses.
night with I Hl-thyinidine and then harvested with an automated cell 
harvester. Simultaneously, the responses of the IUT patients were 
tested against individuals who were either HLA-DR-matched or 
mismatched with the IUT donors. The responses of the IUT patients 
against the different stimulators were compared with responses of  
donors that were HLA-DR matched with the IUT patients and tested 
against the same set of stimulators. In the same test, responder cells 
of both IUT patients and HLA-DR-matched donors were incubated 
with autologous irradiated stimulators. The proliferative response 
was assessed by measuring [3H]-thymidine incorporation using scin­
tillation counting. The stimulation index (SI) is calculated by divid­
ing the counts per minute measured when stimulator and responder 
cells were cultured together by the sum of the counts per minute
when the stimulator and responder cells were cultured separately.
Statistical Ana I vs is
w •
Overall changes in the TCRBV gene usage frequencies between 
the two time points of analysis were determined by correlation coef­
ficients calculation (R2). An R* value o f 1.0 resembles a perfect 
correlation between the first time point of analysis and the second 
time point, whereas an R2 value of .0 resembles no correlation be­
tween the two time points. Differences in the usage frequencies of 
individual TCRBV genes in CD4+ as well as C D S1 T-cell subsets 
between controls and IUT-treated patients were determined by the 
two-tailed unpaired Student’s Mest. When the standard deviations 
in the IUT-treated patients and controls were not equal, the nonpara- 
metric Mann-Whitney U test was used. Results were also corrected 
for the number o f parameters analyzed by the method of Edwards.1(1 
PLT responses were compared with the two-tailed paired or unpaired 
Student’s Mest. For all statistical analyses, a P value of < .05  was 
considered significant.
RESULTS
Spectratyping
Spectratyping o f  the different TCRBV families was determined 
according to the methodology described by Gorski et al.1-1
1 /j.L o f  cDNA was used lor each PCR. PCR conditions were compa-
To determine whether IUT therapy had any influence on 
the TCRB repertoire, we compared the composition of the 
TCRBV repertoire, both before and after IUT treatment, in 
5 IUT patients using a semiquantitative PCR and spectratyp­
ing. To exclude developmental influences, similar experi-
rable to those described above, with the exception that 20 pmol of nients were performed in 5 control patients. In all patients.
a 3' antisense primer was used for each reaction that was end labeled 
with y-( ’"P|-ATP. PCR consisted o f 30 to 40 amplification cycles, 
including a 94°C dénaturation, a 58°C primer annealing, and a 72°C 
extension step Tor 1 minute each. Before transfer o f the radioactive 
PCR products to a prewarmed 6% acrylamide-urea sequencing gel 
(Ultrapure Sequagel-6; National Diagnostics, Atlanta, GA), samples 
were boiled for 5 minutes. Gels were run for 2.5 to 3.5 hours and
dried. The spectratypes were visualized by autoradiog­
raphy and phosphor-imaging.
Validation o f  the Procedure
PCR analysis with H L A -A - and H LA-B-specific probes, fol­
lowed by allele-specific DNA-typing, showed that cord blood o f  the 
IUT treated patients used for analysis was not contaminated with 
donor leukocytes.
PLT
The proliferative alloresponses of 3 IUT-treated patients were 
determined against 8 original IUT donors using PLT. Briefly, 5 X 
10'1 responder cells were cultured with 5 X lO4 irradiated stimulators 
(30 Gy) in 96-well round-bottomed microtiter plates (Costar, Cam­
bridge, MA). Cultures were incubated for 3 days at 37°C in humidi­
fied air containing 5% C 0 2. Cells were subsequently pulsed over-
the first FBS was used as a reference. In IUT-treated patients, 
the first FBS was performed before the onset of transfusion 
therapy to determine the fetal hematocrit or platelet count. 
On average, the first FBS was performed at 26.6 weeks in 
the IUT group compared with 27.4 weeks in the control 
group (Table 1). The composition of the TCRBV repertoire 
of this CB sample was compared with a sample obtained at 
a second time point. For 3 IUT patients (nos. 1, 2, and 5), 
we compared the first FBS with a CB sample before the last 
IUT. This was performed to exclude possible contamination 
with donor leukocytes, because the interval between the last 
IUT and delivery was less than 2 weeks. The second time 
point of measurement was at 35 weeks of gestation, on aver­
age in the IUT group, compared with 38.8 weeks in 
control group (Table 1). The median interval between 
two measurements was 7 weeks for the IUT group and 10 
weeks for the control group.
Semiqua.ntitati.ve Analysis of the TCRBV Gene Usage 
Frequencies Using PCR
The TCRBV repertoires of CD4* and C D 8‘ T-cell subsets 
were analyzed separately because they display different us-
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age profiles.14,17,1,1 The individual TCRBV repertoires in IUT- 
treated patients and controls are shown in Fig 1A and B.
Each individual patient showed a distinct usage pattern of semiquantitative PCR analysis (Fig 1A and B), in the CD4
subset did not result in alterations of the respective spec- 
tratypes. One exception was patient no. 4, in whom major 
changes in the distribution of the CDR3 lengths were noted 
during the course of IUT treatment. Before IUT treatment, 
this patient showed a very restricted TCRB V repertoire that 
differed from all other patients in that they showed a more 
or less binomial distribution of all TCRBV products. These
These results show that, in general, the observed expansions 
or contractions of TCRBV gene usage, as determined by
the various TCRBV gene elements in the CD4+ and CD8+ 
subsets. All TCRBV gene elements were used for each indi­
vidual patient both in IUT-treated patients and controls, ex­
cept for patient no. 4 (Fig 1A). In this patient, several 
TCRBV gene segments remained undetectable in the CD4+ 
subset at 32 weeks of gestation (TCRBV 17 and 19 through 
24). However, most of these genes were detected in cord 
blood after delivery, although the usage frequencies of results were comparable with the semiquantitative PCR,
TCRBV 20 through 22 remained low in this patient.
To determine changes in the overall CD4' and C D 81' 
TCRBV repertoire, correlation coefficient calculations (R2) 
of the first FBS and a sample at a second time point of 
analysis were determined (Table 1). The results showed that, 
in 4 o f 5 IUT-treated patients, significant changes occurred 
in the TCRBV repertoire of the CD4+ subset (mean R2 =  
,301). In 1 patient with hemolytic disease, the overall CD4+ 
TCRBV repertoire was relatively unaffected after IUT ther­
apy (/?* = .851) and was therefore comparable to the control 
patients. In the control group, the CD4+ subset remained 
fairly stable during fetal development (mean R2 =  .899). 
Alterations in the overall usage frequencies of TCRBV fami-
showing a restoration to a more or less normal distribution 
pattern after the course of IUT treatment. Both in the CD44 
and CD8+ subset of the other IUT-treated patients and con­
trols, the individual TCRBV families remained relatively 
unchanged and showed only marginal changes during gesta­
tion (data not shown).
lies within the CD8 subset were observed both in IUT- 
treated patients (mean R2 = .607) and controls (mean R2 = 
.682). Although the control group was quite heterogeneous 
as regards the indication for FBS, similar patterns in the
both of IUT
overall CD4 and CD8 TCRBV repertoire were observed. 
Statistical analysis showed that IUT therapy did not specifi­
cally induce changes in some TCRBV families. The alter­
ations in the TCRBV repertoire were the result o f increased 
and/or decreased usage frequency o f several TCRBV fami­
lies and seemed to be specific for each individual. Similar 
results were observed in the C D 8+ 
treated patients and controls.
Close examination of our results also showed differences 
in TCRBV usage patterns of IUT patients before the onset of 
transfusion therapy when compared with controls. Although 
these differences were observed in several TCRBV families, 
the statistical significance disappeared after multiparameter 
analysis. This was due to loss of statistical power in this 
limited group of patients (data not shown). However, the 
gene usage of TCRBV 19 in the C D 8+ subset of the first FBS 
was significantly increased (uncorrected P  value = .0013, 
corrected P value = .032) in all o f the IUT-treated patients
Proliferative Responses to the Original IUT Donors
Finally, we determined if these molecular changes in the 
CD4 subset of IUT-treated patients were a reflection of an 
allo-reactive response against the IUT donor. Of 3 IUT- 
treated patients (patients no. 1, 2, and 3), sufficient numbers 
o f CB mononuclear cells were available to perform such 
extended studies. Because no pretransfusion samples of these 
fetuses were available, proliferative responses against the 
IUT donors were compared with the responses of healthy 
nontransfused adult donors that were HLA-DR-matched 
with the IUT-treated patients (Fig 3). Both IUT patients 
and HLA-DR-matched responders were also tested against 
autologous mononuclear cells and third-party stimulators 
that were either HLA-DR matched or mismatched with the 
IUT donor. Clear proliferative responses of all IUT patients 
were observed against their original IUT donors (mean SI 
=  16.0). Responses of the IIJT patients against stimulators 
mismatched with the IUT donors were much lower (mean 
SI = 5.4). Establishment of a statistical significance was not 
possible due to the limited number of individuals (mis­
matched with the IUT donor) tested. In all but 2 cases (fetus 
no. 1 against donors no. 2 and 4), the responses were higher 
than those of the
5. ) when compared with the controls
Spectratyping o f  the TCRBV Repertoire
irs against
same set of IUT donors (P = .045). In 3 cases, the SI of 
IUT patients was 75% higher when compared with the HLA- 
DR-matched controls (patient no. 2 against the second IUT 
donor and patient no. 3 against both IUT donors). Patients 
no. 2 and 3 showed higher responses to all IUT donors 
when compared with HLA-DR-matched control responders. 
Patient no. 2 showed a memory response against the second 
IUT donor administered at 23 weeks of gestation. To deter­
mine if these responses were HLA class II specific, the a 11 o-
We have used the technique of spectratyping to investigate reactive responses against third-party individuals (that were 
whether the observed semiquantitative changes o f the HLA-DR matched with the original IUT donor) were 
TCRBV repertoire in the CD4+ subset o f the IUT-treated mined (SI = 12.85). These responses were compan to
patients also resulted in qualitative alterations in the distribu­
tion o f CDR3 size lengths of the [12P] -radiolabeled TCRBV
the allo-reactive capacity against the original IUT
.356), although in individual cases the responses were
transcripts.1' In Fig 2, the distribution o f the CDR3 size clearly lower. The s s reí
lengths of the TCRBV families that showed the most pro- (average, 1,048 counts
nounced modulations of the TCRBV gene usage frequencies counts per minute) were
patients
minute; range, 425 to 2,168
those of the HLA-DR-
are displayed in conjunction with the least affected families. matched controls (average, 349 counts per minute; range,
12496 VICTOR ET AL
Fig 1. The TCRBV gene usage in CD4+ and CD8+ T cells of IUT patients (A) and controls (B) at two different time points of gestation. The 
usage frequency of each individual TCRBV gene element was given as a percentage of the total TCRBV expression. CB, cord blood (at delivery).
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Fi g 2. Radioactive spectratype 
of selected CD4+ TCRBV families 
of lUT-treated patients. Selection 
was based on the most (•) and 
least (O) pronounced alterations 
during the course of IUT treat­
ment. PCR products were ana­
lyzed on a phosphor-imager be­
fore (B) and after (A) the start of 
treatment.
250 to 426 counts per minute) but was corrected for in the 
calculation of the SI.
DISCUSSION
In vivo exposure to atlo-antigens can profoundly change 
the composition of the TCRBV repertoire.10,19,20 For exam-
ple, heart showed quantitative
changes o f several TCRBV families in peripheral blood, 
just before a rejection crisis.20 Munson et all() reported that 
transfusions with HLA-B,DR-shared donor blood can result
in complete deletions o f one or more TCRBV families. In 
vitro experiments have shown a restricted but heterogeneous
, 2 1-23
retai immune
system is prone to modulations of the T-cell compartment. 
This conclusion is derived from the observation that 4 of 5 
IUT patients showed changes of the TCRBV gene usage 
frequencies in the CD4+ subset during the course of therapy.
In 1 IUT patient, this subset remained quite stable and was 
therefore comparable to controls. The control patients 
showed a fairly stable overall composition o f the CD44" sub-
Fig 3. IUT patients (IUT) and donors that were 
HLA-DR matched with these patients (PBL) were 
used as responders (resp ) in the PLT. The original IUT 
donors and third-party individuals that were HLA-DR 
matched (3dp matched) and completely mismatched 
(3dp mm) with the original IUT donors were used 
as stimulators (stirrt). HLA-DR typing; Fetus 1. DR 1,
16(2); PBL, DR 1, 15(2); IUT donor, 1 DR 1, 2 O.
DR11 (5), 4*. DR 3, 4; 3dp matched, 2 O. DR 5, 4*. DR 
3, 4; 3dp mm, •  DR 6, 8. Fetus 2. DR 1, 7; PBL, DR 1, 
7; IUT donor, 1 T. DR 1, 2 A. DR 11(5), 3 V. DR 6, 8; 
3 dp matched, 2 A, DR 5, 3 V, DR 6, 8; 3dp mm, ▼ 
DR 3, 4. Fetus 3. DR 1, 4; PBL, DR 1, 4; IUT donor, 1
. DR 6, 7,, DR 6, 7, 2 U. DR 2, 4; 3dp matched, 1 
2 □ . DR 2, 4; 3dp mm, ■  DR 3, 8,
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set during gestation, at least from 21 weeks o f gestation 
onwards, despite the different indications for FBS in this 
group of patients. The most likely cause of induction o f the 
changes in CD4+ subset of the TCRBV repertoire of the 
IUT-treated patients is the transfusion blood from random 
donors that contains multiple nonself proteins. Although IUT 
blood was filtered before use, it still contained a relatively
Because the procedure of FBS was comparable with IUT- 
treated patients and controls, the stress induced by the proce­
dure cannot explain the observed differences in the TCRBV 
repertoire of the CD4H subset. Furthermore, this procedure 
does not result in any increase in stress indicators such as 
cortisol or /3-endorphin levels.27
The distinctive character of the fetal allo-immune response 
large number of donor leukocytes on which HLA antigens has been acknowledged by several investigators.211-35 CB is
phenotypically immature. For instance, the T-cell subset is 
composed almost exclusively of unprimed naive CD45RA1 
T cells, in contrast to adults expressing this phenotype in 
50% of the T cells.3'’"17 Moreover, all allo-reactive CB T cells 
are of the CD45RA+ phenotype, whereas more than 50% of 
the adult allo-responsive T cells express CD45RO.s# Several 
investigators have proposed that the immature phenotype of 
CB leukocytes might explain the reduced graft-versus-host 
disease after CB transplantation.''0'40 On the other hand, it 
has also been shown that CB is capable of inducing strong 
NK and lymphokine-activated killer (LAK) activity to 
various tumor cells after stimulation with interleukin-2
are expressed. We did not find evidence that IUT treatment 
resulted in a major contraction o f  one or more TCRBV fami­
lies, despite the feet that all IUT treated patients received at 
least one HLA-DR-shared blood transfusion.
In contrast, the CD8+ TCRBV repertoire o f both IUT 
patients and controls changed considerably during gestation.
These alterations most likely reflect maturation of this T- 
cell compartment during fetal development and might have 
masked influences in this subset induced by IUT therapy.
Contrary to the CD8+ subset, the composition o f  the C D 4'
TCRBV repertoire seems to be completed early in gestation, 
because this subset was relatively unaffected during gesta­
tion in the control group.
Although the observed changes in the TCRBV repertoire 
were probably the result of exposure to allo-antigens, the 
influence of hemolytic disease o f the fetus, resulting in se­
vere anemia, cannot be ruled out. It has been observed that 
fetal anemia has an influence on the leukocyte counts. The 
degree of fetal anemia is associated with a corresponding 
decrease in total leukocyte, lymphocyte (T and B cells), 
natural killer (NK), and monocyte count.24,25 In this study, 
we only observed a statistically significant increase in 
TCRBV 19 in the eventual group o f IUT patients before the 
onset of IUT therapy when compared with the controls.
To provide a more detailed insight into the nature o f the 
alterations, we analyzed the distribution o f  CDR3 lengths 
using spectratyping. Surprisingly, no major changes in the 
composition of TCRBV families were observed in the CD4+ 
and C D 8 1 subset of IUT patients and controls. The individ­
ual TCRBV families showed a more or less binomial distri­
bution in both subsets at the two different time points of  
analysis. With the exception of 1 IUT-treated patient (patient 
no. 4), the composition of the TCRBV repertoire of the first 
FBS was even more restricted than was expected on the 
basis of the TCRBV gene usage pattern. However, after the 
course of ILJT treatment, the repertoire showed an almost 
normal distribution. Because we could not observe any sig­
nificant qualitative changes in the CDR3 length o f even the 
most severe quantitatively affected TCRBV families, the ob­
served changes in the C D 41 T-cell compartment were there­
fore merely of a quantitative nature. The explanation behind 
this phenomenon remains speculative. However, these re­
sults are in agreement with a study in which the effect of  
blood transfusion on TCRBV repertoire has been evalu­
ated.26 In 1 patient who received an HLA-B,DR-shared  
transfusion, a clear increase in the usage frequency o f  
TCRBV 21 was observed by semiquantitative PCR. Subse­
quent spectratyping showed no changes in the distribution 
o f the CDR3 lengths. This was in contrast to the monoclonal 
and oligoclonal expansion observed in the C D 8 ' subset of reactive response comparable to that of adults.
(IL-2)31,M’3MI and IL-12.33
The proliferative capacity of CB to allo-antigens is still 
controversial. Some investigators claim that CB is function­
ally immature, resulting in a diminished allo-proliferative 
response to allo-antigens when compared with adults.3 l,34,3M2 
This is in contrast with the observations that the allo-prolifer- 
ative response of CB equals, or is sometimes even superior 
to, those of adults.2IW<1,32,43 Other investigators observed that 
this allo-reactive capacity is lost during the first few weeks 
or months after delivery, reaching adult levels again at ap­
proximately 2 years of age.30 These observations, in combi­
nation with alterations in the TCRBV repertoire after IUT 
therapy, encouraged us to investigate the proliferative capac­
ity of CB of IUT patients against their original donors. These 
results indicated that CB showed a higher proliferative re­
sponse against allo-antigens when compared with adults, but 
CB cells also showed evidence of generating a memory re­
sponse against donor antigens after in vivo exposure. Prim­
ing occurred as early as 23 weeks of gestation. This seems 
to be in contrast with previous in vitro observations that 
CB can produce a strong primary immune response against 
geneic stimulators but exhibits a reduced proliferation 
capacity upon restimulation.'1' However, in vitro and in vivo 
priming might not be comparable. First, not all IUT resulted 
in the establishment of a memory response. Immunization 
might therefore depend on the IUT unit and/or individual 
patient. The number of patients am in was
too small to determine the influence of HLA-sharing between 
donor and recipient and the magnitude of the allo-reactive 
response. Secondly, IUT treatment implicates changes in 
the normal development of the fetal immune system by the 
introduction of allogeneic donor antigens. We have already 
observed that IUT can result in an induction of a more mature 
T-cell phenotype in some patients, including an increase of 
CD45RO-expressing T cells/1'1 This premature maturation of 
the T-cell compartment might be responsible for the alio-
several transfused patients that resulted in altered banding 
patterns (unpublished results).
Patient no. 3, with the highest SI against, both original IUT 
donors, showed the least affected C D 41 TCRBV repertoire.
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These results are in agreement with earlier observations that 
there is no correlation between alterations in the TCRBV 
repertoire and allo-reactive capacity after blood transfu­
sion."'’ Because IUT therapy can seemingly influence the 
TCRBV repertoire and allo-reactive response independently 
of each other, they probably represent two different entities 
prone to modulations by blood transfusion.
logical tolerance to major histocompatibility complex antigens. Proe
Nall Acad Sci USA 78:3844, 19 8 1
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